Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$492.9MCash on Hand
63.4mo Cash Runway
Follow AKTS by emailGet an email when AKTS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AKTS, unsubscribe in one click. Privacy
📣 What AKTS Says Is Next
in 2027 · “AKY-2519: Expect preliminary data from the ongoing Phase 1b BActinium-1 trial in 2027.”
Company press release, Nov 12, 2026 · SEC filing
first quarter of 2027 · “AKY-1189: Expect preliminary data from the ongoing Phase 1b NECTINIUM-2 trial in the first quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
second half of 2026 · “AKY-2519: o Expect to commence Phase 1b BActinium-2 basket trial in lung and other B7-H3 expressing solid tumor cancers in the second half of 2026. o Expect preliminary data from Phase 1b mCRPC clinical trial in 2027.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Earnings Reported Q3 2026 results: cash and securities of $492.9 million, funding operations into 2029. Net loss was $29.9 million, versus $15.5 million a year earlier. R&D expense rose to $32.1 million. Preliminary AKY-1189 data expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 13, 2026 ·
Earnings Reported Q2 2026 cash, equivalents and marketable securities of $517.3 million, funding operations into 2029. Collaboration revenue rose to $3.4 million, R&D to $25.3 million, G&A to $7.0 million, and net loss to $24.1 million. Released data on AKY-2519 imaging and dosimetry. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2027 · Phase 1 · Recruiting · A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors Registry primary completion date, not a results date
Dec 2027 · Phase 1 · Recruiting · A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer Registry primary completion date, not a results date
Dec 2028 · Phase 1 · Recruiting · A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AKTS holds $492.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $23.3M/quarter from operations,
an estimated runway of 63.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:0 · Low
Cash runway 63 months
S-1 registration (Dec 2025) +8
Company says cash lasts into 2029 -15Based upon our current operating plans, we believe our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operations into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Jan 9, 2026 · Underwritten offering, $318M · 424B4
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AKTS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.